Twist Bioscience Reports Q2 2026 Earnings: Key Financial Highlights
Twist Bioscience posted $102.6 million in Q2 2026 revenue, beating Wall Street’s consensus by a razor-thin margin but falling short of the high-end guidance the company set last quarter. Net income clocked in at a loss of $14.2 million, a narrower gap than the $21.1 million loss in Q2 2025, signaling cost controls are finally biting. Earnings per share landed at -$0.26, an improvement from last year’s -$0.41 but still firmly in the red, according to Yahoo Finance.
Synthetic DNA orders, Twist’s core business, jumped 19% year-over-year, offsetting slack in pharma partnerships and a 7% slide in biopharma services revenue. Gross margin reached 44.3%, up 310 basis points from Q2 2025, as the company squeezed more profit out of its DNA manufacturing platform and exited two underperforming product lines. Operating expenses fell 11%—the first quarterly drop since 2023—driven by layoffs and tighter R&D spending.
CEO Emily Leproust called the quarter “a turning point,” citing the company’s return to sequential revenue growth and progress toward positive cash flow. CFO Jim Thorburn emphasized the company’s “disciplined capital allocation” and said Twist would “prioritize high-margin segments and defer non-core initiatives.” Both executives projected confidence but offered few specifics on the timing of a return to profitability.
Market Reaction and Immediate Impact on Twist Bioscience's Stock and Industry Position
Twist shares opened down 3.8% in premarket trading before clawing back losses to close flat, reflecting mixed sentiment—relief over improving margins, but concern about slowing top-line growth. Options volume spiked 40% over the daily average as traders bet on volatility around the call. Short interest remains elevated at 9.2% of float, showing skepticism persists despite operational improvements.
Analysts at Morgan Stanley and Jefferies reiterated “Hold” ratings, citing execution progress but flagging persistent pricing pressure in synthetic DNA as Illumina and Ginkgo Bioworks ramp up their own offerings. Several hedge funds trimmed positions last quarter, wary of Twist’s exposure to academic and early-stage biotech customers who remain cautious on spending. Still, the company’s 19% growth in core DNA orders stands out in a sector where most rivals are posting mid-single-digit gains at best.
Twist announced a restructuring of its pharma services segment, consolidating operations from three sites to one and cutting 60 jobs. The company also paused plans for a European manufacturing hub, freeing up $18 million in capex for higher-yielding projects. These moves telegraph a shift from growth-at-all-costs to discipline—a theme echoing across the sector as rates stay high and investor patience thins.
What to Expect Next: Guidance and Strategic Outlook from Twist Bioscience
Management guided for Q3 2026 revenue of $106–108 million and full-year revenue of $413–418 million, both slightly ahead of consensus but contingent on a rebound in pharma services and stable academic funding. Gross margin is expected to expand to 45–46% by year-end as the company finishes its transition to automated DNA synthesis workflows.
The pipeline for 2026 includes a launch of Twist’s long-read DNA synthesis platform—expected to open new markets in gene therapy and cell engineering—as well as an expansion of its antibody discovery partnerships with large pharma. CTO Bill Banyai teased a “major customer win” in the agricultural biotech space, with details to come in August.
Risks remain: management flagged ongoing pricing compression, uncertainty around NIH grant cycles, and rising input costs for key reagents. On the opportunity side, Twist is betting on increased demand from mRNA vaccine developers and a rebound in China-based orders, which cratered in 2025 but show early signs of life.
Investors should watch for the August product launch, updates on the European expansion pause, and any shifts in guidance at the next quarterly call. With sector M&A heating up—Thermo Fisher and Danaher both circling smaller players—Twist could find itself a target if it keeps closing the margin gap. For now, the company has bought itself time with better cost discipline, but the next two quarters will determine whether that’s enough to shift the narrative from survival to growth.
⚠️ Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.
The Bottom Line
- Twist Bioscience posted improved margins and narrowed losses, signaling better cost controls.
- Market reaction was mixed due to concerns about slowing revenue growth despite operational progress.
- Elevated short interest and increased options trading highlight ongoing investor skepticism and volatility.
